NIH Clinical Center logo     America's Clinical Research Hospital File folder iconExplore the NIH
Clinical Center
Search the Studies - NIH Clinical Research Studies

Protocol Details

Characterization of the Innate Immune Response in Healthy NIH Employees at Baseline and After Immunization with the H1N1 Vaccine

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Heart, Lung and Blood Institute (NHLBI)

Recruitment Detail

Type: Completed Study; data analyses ongoing
Gender: Male & Female
Min Age: 18
Max Age: N/A

Referral Letter Required


Population Exclusion(s)


Special Instructions

Currently Not Provided


Post Swine Flu Blood Samples;
Biologic Sample Collection;
Laboratory Research Samples;
H1N1 Vaccine Samples

Recruitment Keyword(s)

Healthy Volunteer


Healthy Volunteers

Investigational Drug(s)


Investigational Device(s)




Supporting Site

National Heart, Lung, and Blood Institute


- The Center for Human Immunology, Autoimmunity, and Inflammatory Diseases is conducting research investigating how the swine flu (H1N1) vaccine affects the immune system. The exposure to the new swine flu vaccine gives us a rare opportunity to learn about how the human immune system responds to a new vaccine.

- Researchers are interested in collecting blood samples from individuals who have received the vaccine. Participants will be selected from a group of healthy volunteers who will be receiving the H1N1 vaccine because it is mandatory for their work at the National Institutes of Health. This protocol will be one of the first studies to characterize the human innate immune response to H1N1 vaccine.


- To collect blood samples for research purposes before and after participants receive a standard non-research vaccination against swine flu (H1N1).


- Healthy individuals 18 years of age and older who are employees of the National Institutes of Health.

- Individuals who have had confirmed cases of influenza in the past year are not eligible to participate.


- Participants will be admitted for a 36-hour inpatient stay, during which blood samples will be taken frequently. Participants will have a standard intravenous catheter (similar to the one used for intravenous infusions) put in place to avoid multiple needle sticks.

- Participants will be assigned into one of two groups; the two groups differ in the timing of blood draws but not in the overall amount of blood drawn.

- Group 1: Blood samples 30 minutes before and immediately before vaccination. Additional samples will be taken 2, 4, 6, 8, 10, 12, 14, 16, 18, 24, 30, and 36 hours after vaccination.

- Group 2: Blood samples 30 minutes before and immediately before vaccination. Additional samples will be taken over the following 36 hours, with exact timing to be determined based on the findings from group 1.

- All participants will provide blood samples 7 days after being released from the inpatient stay.

- Because of the amount of blood being drawn for research, participants should not donate blood or take part in any other protocols that collect blood while participating in this study.

--Back to Top--



- NIH employees scheduled to receive the H1N1 vaccine through OMS

- Healthy status confirmed by History, Physical Exam and blood work through the CHI Screening Protocol

- Age 18 years and older (no upper limit)

- Able to comprehend the investigational nature of the protocol and provide informed consent


- Recipient of another vaccine or immune modulating drug within 6 months prior to study entry. Seasonal influenza vaccine may be administered up to 3 days prior to enrollment or after completion of study participation (day 7 blood draw)

- Confirmed influenza within the past 1 year

- Severe allergies to eggs or their products

- Prior severe reactions to vaccines

- Participation on any blood collection or blood donation procedure during study that will bring the total blood draw > 550m1 over 8 weeks.

- Current pregnancy (women of child bearing potential must have a negative serum pregnancy test done on screening within 1 week of protocol accrual)

--Back to Top--


Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 Jan 8;289(2):179-86

Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature. 2009 Jun 18;459(7249):931-9

Zimmer SM, Burke DS. Historical perspective--Emergence of influenza A (H1N1) viruses. N Engl J Med. 2009 Jul 16;361(3):279-85. Epub 2009 Jun 29

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Shira Y. Perl, M.D.
National Heart, Lung and Blood Institute (NHLBI)
BG 10 RM 7N116B
(301) 594-0512

Shira Y. Perl, M.D.
National Heart, Lung and Blood Institute (NHLBI)
BG 10 RM 7N116B
(301) 594-0512

Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

Clinical Trials Number:


--Back to Top--


Contact the Patient Recruitment and Public Liaison Office for:

  • Details on how to participate in a study
  • Details on how to refer a patient to a study

NIH Clinical Studies Information Request

Contact the Office of Communications for:

  • General information about the NIH Clinical Center

Contact the Department Clinical Research Informatics, (DCRI) for:

  • Technical questions about Adobe Acrobat and the PDF format
  • Technical questions about this web server